F/m Emerald Life Sciences Innovation ETF LFSC
Source: Yahoo Finance (opens in a new tab) Observed · 1 day ago Quotes may be delayed
- Net expense ratio
- 0.54%
- Net assets
- $105.1M
- Holdings
- 40
- 12-month distribution yield
- Unavailable
- Asset class
- Equity
F/m Emerald Life Sciences Innovation ETF (LFSC) is an exchange-traded fund listed on the Nasdaq in the United States, issued by F/m Investments. Its category is Equity · US (equity). Its last price was US$42.56 on 20 Oct 2026. Its net expense ratio is 0.54% a year, from its prospectus dated 31 Dec 2025. It reported net assets of US$105.06 million as of 31 May 2026. Its latest holdings report lists 40 holdings as of 31 May 2026. No distributions are recorded for it over the last 12 months.
Fees
- Total annual operating expenses (gross)
- 0.79%
- Net, after fee waivers or reimbursements
- 0.54%
- Management fee
- 0.79%
- Prospectus date
- 31 Dec 2025
- Filed with the SEC
- 5 Jan 2026
Size and reporting
- Net assets
- $105,060,635
- Total assets
- $105,107,727
- Holdings as of
- 31 May 2026
- Report made public
- 28 Jul 2026 (58 days after the month end)
Top holdings
Largest 25 of 40 positions, as of 31 May 2026. Weight is the percent of net assets the fund reported.
| # | Holding | Identifier | Weight | Value (USD) | Type | Country | Currency |
|---|---|---|---|---|---|---|---|
| 1 | Travere Therapeutics Inc | US89422G1076 | 7.67% | $8.1M | Equity (common) | United States | USD |
| 2 | Cogent Biosciences Inc | US19240Q2012 | 7.53% | $7.9M | Equity (common) | United States | USD |
| 3 | LivaNova PLC | GB00BYMT0J19 | 7.11% | $7.5M | Equity (common) | United Kingdom | USD |
| 4 | Spyre Therapeutics Inc | US00773J2024 | 6.41% | $6.7M | Equity (common) | United States | USD |
| 5 | Guardant Health Inc | US40131M1099 | 5.52% | $5.8M | Equity (common) | United States | USD |
| 6 | Mirum Pharmaceuticals Inc | US6047491013 | 4.92% | $5.2M | Equity (common) | United States | USD |
| 7 | Corcept Therapeutics Inc | US2183521028 | 4.79% | $5.0M | Equity (common) | United States | USD |
| 8 | United Therapeutics Corp | US91307C1027 | 4.16% | $4.4M | Equity (common) | United States | USD |
| 9 | VeraDermics Inc | US9229671048 | 3.42% | $3.6M | Equity (common) | United States | USD |
| 10 | Savara Inc | US8051111016 | 3.22% | $3.4M | Equity (common) | United States | USD |
| 11 | Cytokinetics Inc | US23282W6057 | 3.16% | $3.3M | Equity (common) | United States | USD |
| 12 | Nektar Therapeutics | US6402683063 | 3.14% | $3.3M | Equity (common) | United States | USD |
| 13 | Trevi Therapeutics Inc | US89532M1018 | 3.12% | $3.3M | Equity (common) | United States | USD |
| 14 | Dianthus Therapeutics Inc | US2528281080 | 3.09% | $3.2M | Equity (common) | United States | USD |
| 15 | Axsome Therapeutics Inc | US05464T1043 | 2.84% | $3.0M | Equity (common) | United States | USD |
| 16 | Billiontoone Inc | US0901681058 | 2.73% | $2.9M | Equity (common) | United States | USD |
| 17 | TransMedics Group Inc | US89377M1099 | 2.68% | $2.8M | Equity (common) | United States | USD |
| 18 | Viridian Therapeutics Inc | US92790C1045 | 2.23% | $2.3M | Equity (common) | United States | USD |
| 19 | ICU Medical Inc | US44930G1076 | 2.09% | $2.2M | Equity (common) | United States | USD |
| 20 | Corvus Pharmaceuticals Inc | US2210151005 | 1.95% | $2.1M | Equity (common) | United States | USD |
| 21 | Palvella Therapeutics Inc | US6979471090 | 1.95% | $2.0M | Equity (common) | United States | USD |
| 22 | Ceribell Inc | US15678C1027 | 1.55% | $1.6M | Equity (common) | United States | USD |
| 23 | Globus Medical Inc | US3795772082 | 1.27% | $1.3M | Equity (common) | United States | USD |
| 24 | Xeris Biopharma Holdings Inc | US98422E1038 | 1.22% | $1.3M | Equity (common) | United States | USD |
| 25 | Bridgebio Pharma Inc | US10806X1028 | 1.17% | $1.2M | Equity (common) | United States | USD |
Breakdowns
Sums of reported weights over every position in the report. Totals can differ from 100% because of derivatives, borrowing and cash.
Asset type
| Type | Weight | Bar |
|---|---|---|
| Equity (common) | 100.04% | |
| Short-term investment vehicles (cash funds) | <0.01% |
Country
| Country | Weight | Bar |
|---|---|---|
| United States | 91.98% | |
| United Kingdom | 7.11% | |
| Singapore | 0.95% |
Currency exposure
| Currency | Weight | Bar |
|---|---|---|
| US dollar (USD) | 100.04% |
Sector
| Sector | Weight | Bar |
|---|---|---|
| Health Care | 35.71% | |
| Technology | 1.99% |
Source: SEC Form N-PORT (opens in a new tab) Holdings as of
Distributions
No distributions in the last five years
Filings and sources
- Form N-PORT report for May 2026 (opens in a new tab)
- Prospectus filing with the fee table (opens in a new tab)
- All SEC filings for this fund series (S000088167) (opens in a new tab)
- Nasdaq Trader symbol directory (opens in a new tab)
- Yahoo Finance quote and distributions (opens in a new tab)
- How the ETF figures are collected
Compare with
Largest funds in the same category:
- LFSC and VTI Vanguard Morningstar Total Stock Market ETF
- LFSC and VOO Vanguard S&P 500 ETF
- LFSC and IVV iShares Core S&P 500 ETF
- LFSC and QQQ Invesco QQQ Trust, Series 1